NEW YORK CITY, NY / ACCESS Newswire / January 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Forbes does not accept payment for placement on lists.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback